Target intelligence / Profile preview

Pathogenic bacterial species in the gut

Molecular classification
Other (bacterial species, not a single molecular family or classification)
01

Overview

Pathogenic bacterial species in the gut refer to bacteria capable of causing disease within the gastrointestinal tract. Unlike beneficial or commensal microbes, these pathogens may produce toxins, promote inflammation, disrupt normal gut function, and interact adversely with the host immune system. Common examples include toxin-producing strains of Clostridioides difficile, Salmonella enterica, pathogenic Escherichia coli, Staphylococcus aureus, and certain Fusobacterium species. Their presence and overgrowth are linked to infections, inflammatory bowel disease, colorectal cancer, and systemic illnesses. Treatment strategies target these organisms using antibiotics, bacteriophage therapy, probiotics, and restoration of normal microbiota composition. Due to the broad and diverse nature of this group, "Pathogenic bacterial species in the gut" does not represent a discrete drug target but is an umbrella term for multiple disease-associated bacterial populations[1][3][5][6][7].

Other names
Pathogenic gut bacteriaEnteric pathogensHarmful intestinal bacteriaPathogenic species of gut microbiota
02

Mechanism of action

Inhibition of bacterial growth or replication; Disruption of cell wall synthesis; Interference with DNA or protein synthesis; Microbiota modulation and competitive exclusion

03

Biological functions

InfectionToxin productionInflammation inductionColonization resistance disruptionMetabolic disturbance
04

Disease associations

InfectionInflammationCancer (especially colorectal cancer)Metabolic diseaseGastrointestinal disordersOther systemic diseases
05

Safety considerations

Antibiotic resistanceOff-target effects (antibiotics affecting commensal bacteria)Risk of dysbiosisPotential for opportunistic pathogen growth following therapy
06

Interacting drugs

Antibiotics (e.g., metronidazole, vancomycin, ciprofloxacin)

4 more in the full profile.

07

Biomarkers

Fecal bacterial count or composition (e.g., presence of Clostridioides difficile, Escherichia coli O157:H7, Salmonella enterica, Staphylococcus aureus)Fecal calprotectin (inflammation)Bacterial toxins (e.g., Shiga toxin, C. difficile toxins)

Beyond the preview

Go deeper on Pathogenic bacterial species in the gut.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacterial species in the gut.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call